ASTRO Annual Meeting
American Society for Radiation Oncology honors two Gold Medal recipients
The American Society for Radiation Oncology presented the ASTRO Gold Medal to two of its members.
Adding radiation to hormone therapy slows progression of oligometastatic prostate cancer
Adding localized radiation therapy to intermittent hormone therapy extended PFS among men with oligometastatic prostate cancer, data from the randomized phase 2 EXTEND trial showed.
Radiation therapy for asymptomatic bone metastases prolongs survival, prevents pain
Palliative radiation therapy for high-risk asymptomatic bone metastases significantly prolonged OS while reducing skeletal-related events compared with standard therapy, phase 2 trial results showed.
Machine-learning approach using step counts predicts hospitalization during radiotherapy
An artificial intelligence model appeared to predict the likelihood of unplanned hospitalizations during chemoradiation therapy among a cohort of patients with various cancer types.
Increased radiation dose after missed treatments may benefit some patients with NSCLC
Some patients with non-small cell lung cancer who miss radiation treatments may benefit from higher radiation doses, according to a study presented at American Society for Radiation Oncology (ASTRO) Annual Meeting.
Hypofractionated radiation therapy ‘new standard of care’ for high-risk prostate cancer
Men with high-risk prostate cancer who received a shorter course of radiation therapy had similar survival and recurrence rates as those who received a longer, standard radiation therapy course, phase 3 trial results showed.
Hypofractionated whole-breast irradiation safe, effective for certain early breast cancers
A 3-week course of hypofractionated whole-breast radiation therapy appeared as safe and effective as a conventional treatment course among patients with early-stage breast cancer at high risk for recurrence.
Adding radiation therapy to sorafenib extends survival in advanced liver cancer
The addition of stereotactic body radiation therapy to sorafenib extended OS among patients with advanced hepatocellular carcinoma, results of the randomized phase 3 NRG Oncology/RTOG 1112 trial showed.
First-in-human study of proton FLASH radiotherapy produces ‘very promising’ results
Proton FLASH radiotherapy showed clinical feasibility in a first-in-human study of patients with cancer and painful bone metastases, according to data presented at American Society for Radiation Oncology Annual Meeting.
Sexual health assessment far less common for women vs. men undergoing cancer brachytherapy
Assessment of sexual function occurred far less often among women undergoing brachytherapy for cervical cancer than men who received the internal radiotherapy for prostate cancer, according to results of a retrospective analysis.